Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12134032 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL723666 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL8017511 | 0.94 | — | — | |
| SCHEMBL2742856 | 0.90 | ALDH1A1 (0.32) | ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL4609242 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL25566315 | 0.86 | ALDH1A1 (0.40) | ALDH1A1TSHRL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL11030766 | 0.84 | ALDH1A1 (0.40) | ALDH1A1TSHRL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL13864131 | 0.84 | ALDH1A1 (0.40) | ALDH1A1TSHRL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL5159311 | 0.84 | ALDH1A1 (0.40) | ALDH1A1TSHRL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL5163869 | 0.84 | ALDH1A1 (0.40) | ALDH1A1TSHRL3MBTL1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230157290-A1 | ALKENE-CONTAINING CARBOXYLATE COMPOUND AND USE THEREOF | JIANGSU YANGNONG CHEMICAL CO., LTD (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20180194793-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110172299-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20090197962-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0763524-B1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO CO (JP) | 2000-08-23 | — | — | EP | disclosed |
| US-6040339-A | TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA OR ARTERIOSCLEROSIS IN A MAMMAL | SANKYO COMPANY, LIMITED (JP) | 2000-03-21 | — | — | US | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| US-5880147-A | Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use | SANKYO COMPANY, LIMITED (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172299-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | TUBB6, TUBB3, TUBB2A | ALDH1A1 587/4885TSHR 3912/4885L3MBTL1 4672/4885 |
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885TSHR 3270/4885L3MBTL1 1721/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | ALDH1A1 4764/4885TSHR 2893/4885L3MBTL1 694/4885 |
| US-20090197962-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | PTGIS, PTGES, PTGS1 | ALDH1A1 1258/4885TSHR 3556/4885L3MBTL1 4827/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885TSHR 3270/4885L3MBTL1 1721/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ALDH1A1 287/4885TSHR 4730/4885L3MBTL1 1418/4885 |
| US-20230157290-A1 | ALKENE-CONTAINING CARBOXYLATE COMPOUND AND USE THEREOF | DDT, ALK, ACMSD | ALDH1A1 33/4885TSHR 2268/4885L3MBTL1 2089/4885 |
| US-20180194793-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | ALDH1A1 3169/4885TSHR 3730/4885L3MBTL1 1005/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | ALDH1A1 438/4885TSHR 4392/4885L3MBTL1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.